Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Liabilities (2016 - 2026)

Anika Therapeutics has reported Total Liabilities over the past 17 years, most recently at $45.5 million for Q1 2026.

  • Quarterly Total Liabilities rose 7.77% to $45.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $45.5 million through Mar 2026, up 7.77% year-over-year, with the annual reading at $46.8 million for FY2025, 3.99% down from the prior year.
  • Total Liabilities was $45.5 million for Q1 2026 at Anika Therapeutics, down from $46.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $68.0 million in Q2 2022 and troughed at $40.0 million in Q2 2025.
  • The 5-year median for Total Liabilities is $54.9 million (2023), against an average of $53.4 million.
  • Year-over-year, Total Liabilities plummeted 34.05% in 2022 and then grew 8.92% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $63.6 million in 2022, then dropped by 8.18% to $58.4 million in 2023, then decreased by 16.48% to $48.8 million in 2024, then fell by 3.99% to $46.8 million in 2025, then dropped by 2.82% to $45.5 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Total Liabilities are $45.5 million (Q1 2026), $46.8 million (Q4 2025), and $42.6 million (Q3 2025).